<DOC>
	<DOCNO>NCT00003084</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness combination chemotherapy consist paclitaxel , etoposide , estramustine compare ketoconazole plus doxorubicin , vinblastine , estramustine treat patient prostate cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Ketoconazole Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine clinical benefit two combination chemotherapy regimens , paclitaxel , etoposide , estramustine v ketoconazole , doxorubicin , vinblastine , estramustine patient androgen independent prostate cancer , measure prostate specific antigen ( PSA ) -based response rate , time progression , overall survival . II . Identify promise regimen use phase III trial base toxic effect , PSA-based response rate , clinical benefit . OUTLINE : This randomize multicenter study . Patients stratify accord risk group : low volume disease ( 2 lesion bone scan ) , intermediate volume ( 2 bone lesion confine axial skeleton ) , high volume ( bone lesion appendicular skeletal visceral lesion ) . Patients randomize one two treatment arm . Arm I : Patients receive oral estramustine three time day oral etoposide twice daily day 1-14 paclitaxel IV 1 hour day 2 . Treatment repeat every 21 day . Arm II : Patients receive doxorubicin IV day 1 , 15 , 29 , vinblastine IV day 8 , 22 , 36 , oral ketoconazole three time day day 1-7 , 15-21 , 29-35 , oral estramustine three time day day 8-14 , 22-28 , 36-42 . This regimen consist 6 week alternate chemotherapy 2 week rest , 8 week course . Treatment continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 92 patient ( 46 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Androgen independent disease progression Castrate testosterone level le 40 ng/dL ( medically achieve , treatment must maintain continuously ) Prostate specific antigen ( PSA ) least 4 ng/mL rise least 2 consecutive measurement No variant histology ductal carcinoma ( endometrioid cribiform ) small cell carcinoma Brain metastasis control PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 03 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 9.5 g/dL ( without transfusion support ) Hepatic : Bilirubin transaminase less 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL OR Estimated creatinine clearance least 35 mL/min Cardiovascular : No clinical history heart disease Normal ECG OR Ejection fraction ( ECHO , MUGA , ventriculography ) least 45 % Other : Spinal cord compression control No active peptic ulcer disease No active , likely become active , second malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior ketoconazole Chemotherapy : No prior doxorubicin , vinblastine , estramustine , paclitaxel , etoposide No great one prior cytotoxic therapy No concurrent chemotherapy At least 8 week since prior mitomycin At least 60 day since prior suramin Endocrine therapy : No antiandrogen therapy flutamide nilutamide within 4 week ( 6 week bicalutamide ) without response OR Progression since antiandrogen withdrawal Prior dexamethasone therapy discontinue Radiotherapy : At least 10 week since prior strontium Sr 89 1 prior regimen No concurrent strontium Sr 89 Surgery : Not specify Other : No concurrent therapy prostate cancer No concurrent H2 blocker , omeprazole , antacids No concurrent terfenadine astemizole</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Estramustine</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Vinblastine</keyword>
</DOC>